News & Updates

Join us at JPM2025 (Jan 2025)

We’re excited to attend JPM 2025 and share updates on our pioneering chemistry platform. Our latest data from the ALS program will also be available for discussion.

Let’s connect to explore investment or partnership opportunities, whether you’re familiar with our work or learning about us for the first time. We look forward to engaging with fellow innovators and advancing collaborations that drive impact.

Ilios Therapeutics Presents at LabCentral's Inaugural Mind Matters Scientific Symposium (Nov 2024)

Ilios Therapeutics was honored to present a poster at LabCentral's inaugural Mind Matters Scientific Symposium, which brought together leading experts to discuss advancements in neurodegenerative disease research from clinical, preclinical, and investment perspectives.

We extend our gratitude to LabCentral, especially Johannes Fruehauf and Sezin Yigit, PhD, for organizing this impactful event, and to all participants for their invaluable insights.

SCBio Showcases Ilios as a MassBio Success (Nov 2024)

Ilios was honored to be showcased by SCBio as an example of innovation emerging from the MassBio ecosystem during an event in Charleston, South Carolina, just before Thanksgiving. The opportunity to highlight our work in developing multi-functional therapeutics for neurodegenerative diseases underscores the importance of a strong, supportive biotech community.

We extend our gratitude to Kendalle O'Connell, James Chappell, and the event organizers for their leadership and support. Thanks to the ecosystem for helping advance our mission of tackling complex diseases with innovative solutions.

Ilios participates to the inaugural workshop for Project Mosaic (Nov 2024)

Ilios joined the inaugural workshop for Project Mosaic, an initiative focused on developing robust and translatable models for sporadic ALS. Held in Washington, DC, the event brought together drug makers, CROs, academic researchers, nonprofits, and government leaders to discuss priorities like genetically representative models, TDP-43 mislocalization, and cell survival as key phenotypes for advancing ALS research.

We thank Bernie Zipprich and the Project Mosaic team for their exceptional leadership and commitment to collaboration. Bernie, your resilience inspires us to drive impactful research. Ilios is excited to continue supporting this initiative and contributing to solutions that bring us closer to meaningful progress in ALS.

Ilios wins the Boston Biotech PitchFest (Nov 2024)

Ilios was selected as one of the three winners for the 2024 edition of the Boston PitchFest hosted by Portal Innovations.

Over 80 innovative biotech spartups participated in a fun eveneing of elevator pitches culminating in a few full presentations.

Eli Lilly selects Ilios for Grand Challenge in Neuroscience (Aug 2024)

Special thanks to Eli Lilly and Company for hosting Ilios Therapeutics and other 9 incredible startups for their Grand Challenge in Neuroscience Finals in their Indianapolis HQ, in partnership with Nucleate.

Zaven Kaprielian and Luca Giani had the chance to discuss Ilios’ innovative approach to develop multi-functional therapeutics to combat neurodegenerative diseases with several stakeholders at Lilly.

Check out The Dish with Johannes Interview about Ilios! (Jul 2024)

The second episode of LabCentral new video series, 'The Dish with Johannes' just dropped on LC's Youtube channel!

In this episode, Johannes Fruehauf sits down with Luca Giani, CEO & Co-Founder of Ilios Therapeutics journey into the world of biotech, Ilios's novel approach to neurodegenerative diseases, and the simple question that started it all.

Ilios is Among First 14 Companies to Join Alzheimer's Moonshot Community (May 2024)

The initiative, supported by Gates Ventures and the Alzheimer’s Drug Discovery Foundation (ADDF), spans the full spectrum of Alzheimer’s care, from awareness and early detection to diagnosis, treatment, and support.

We are excited to join this vibrant community and advance in our therapeutics drug development.

Ilios presents at the Harvard President Innovation Challenge (May 2024)

Ilios Therapeutics presented as one of five teams selected in the Health and Life Science Harvard University President's Innovation Challenge, describing our mission of generating multi-functional therapeutics to combat neurodegenerative diseases.

We invite you to watch the presentation and join us in our mission.

Ilios to present at the 2024 MassBio Align Summit (Apr 2024)

At Ilios, we are thrilled to announce our participation in MassBio 2024 Align Summit organized in collaboration with McKinsey & Company and Locust Walk. We'll be showcasing our work on multi-targeted therapeutics against neurodegenerative diseases on April 25 at the Royal Sonesta Hotel. Join us for a day filled with partnering, keynotes, panel discussions and presentations from other innovative biotech companies.

Ilios attends JPM (Jan 2024)

Ilios's COO, Lisa Paborsky, and CEO, Luca Giani, attended the JPM 2024 Healthcare Conference in San Francisco. Among several productive meetings with potential partners and investors, Ilios was able to showcase its advancements towards a lead candidate selection for its ALS program.

Ilios to present at Bio Investor Forum in SF (Oct 2023)

Ilios to showcase drug development ALS program in partnering and venture funding BIO Investor Forum. Conference is focused on accelerating the progress of new therapeutic technologies.

Selected among HBS 2023-2024 Blavatnik Fellows (Jul 2023)

Ilios' CEO selected among the 2023-2024 cohort of Blavatnik Fellows. Celebrating its tenth anniversary, the Blavatnik Fellowship in Life Science Entrepreneurship selects five high-potential individuals from the Harvard MBA and PhD ecosystem.

One of five biotech startups in MassBioDrive S23 cohort (Apr 2023)

MassBioDrive is run by MassBio, Massachusetts’ leading organization in life sciences, promoting industry growth, by representing 1,400+ members.

Through the eight week accelerator, we will get hands-on expert guidance, mentorship from biopharma leaders, and access to MA's largest biopharma network.

One of 11 ventures in 2023 Pagliuca Harvard Life Lab (Feb 2023)

Proud to be one of the 11 ventures to kick off the 2023 cohort of the Pagliuca Harvard Life Lab. The Pagliuca Harvard Life Lab is home to some of the most innovative minds working tirelessly to address some of the most pressing health challenges faced by our society. With cutting-edge resources and a collaborative environment, the Life Lab is the perfect breeding ground for breakthroughs that have the potential to change lives.

Presented at Biotech Showcase during JPM Conference (Jan 2023)

Our Cofounder and CEO, Luca Giani, presented Ilios Therapeutics' cutting-edge science and strategy on January 11, 2023 at the Biotech Showcase in San Francisco as part of the annual J.P. Morgan biotech conference alongside several other breakthrough technologies.

Ilios Accepted into the Boston Chapter of Nucleate (Dec 2022)

Nucleate facilitates the formation of pioneering life sciences companies, providing support for life science companies working on high-potential technologies.

Ilios joins the Pagliuca Harvard Life Lab (Dec 2022)

Ilios Therapeutics has officially joined the Pagliuca Harvard Life Lab operated by LabCentral. This state-of-the-art facility will provide us with the instruments, resources and support we need to advance our experimental plan and perform assays to test our proprietary new chemical entities against neurodegenerative diseases.

Ilios Joins MassChallenge 2022 Early-stage Startup Cohort (Jun 2022)

Ilios Tx joins more than 200 other ventures as part of this year's MassChallenge accelerator. Through the program Ilios gains access to MassChallenge's global network, world-class mentoring from industry experts, tailored programming, and unrivaled access to corporate partners.

Ilios' Co-Founder Highlighted by NASDAQ (May 2023)

NASDAQ highlighted the work of Ilios Tx co-founder and CEO, Luca Giani, in creating innovative therapies against neurodegenerative diseases. The showcase is part of an initiative celebrating social entrepreneurs advancing the UN SDGs.

Ilios Welcomes Inaugural Internship Class (May 2023)

Ilios Tx is proud to announce its first internship class: Lourdes Amieva, Fernando Gómez, Laura Mena, and Maria Natera. The four biotech graduates will help Ilios advance its pathway to IND and continued drug discovery, both with traditional research and novel bioinformatic computational methods.

Finalist for Harvard President Innovation Challenge (Apr 2022)

The Presidential Innovation Challenge showcases some of Harvard's most promising student and alumni ventures. Selected teams have the opportunity to win a portion of non-dilutive funding, made possible by a gift from the Bertarelli Foundation.

Ilios Secures Funding from Allston Venture Fund (Apr 2022)

The Allston Venture Fund provides pre-seed, equity free investment for promising ventures led by Harvard students. The fund is backed by Bain Capital, General Catalyst, GETTYLAB, Highland Capital, Polaris Partners, and Underscore VC.